Sygnis sells its own-brand TruePrime kits through its website and an international distributor network. A new enzyme, SunScript, has been added to the range. Kits may also be sold as OEM products with next-generation sequencing systems. A new kit for research in cancer diagnosis and monitoring could be added in 2016. Cash at 31 March was €2.5m. Q115 had revenues of €76k; total cash outflow was €1.29m.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Adding to the brand
Sygnis sells its own-brand TruePrime kits through its website and an international distributor network. A new enzyme, SunScript, has been added to the range. Kits may also be sold as OEM products with next-generation sequencing systems. A new kit for research in cancer diagnosis and monitoring could be added in 2016. Cash at 31 March was €2.5m. Q115 had revenues of €76k; total cash outflow was €1.29m.